

學歷

平成 9 年 3 月 慶應義塾高等学校卒業
平成 9 年 4 月 慶應義塾大学医学部入学
平成 15 年 3 月 慶應義塾大学医学部卒業

職歷

平成 1 5 年	4 月	東京都済生会中央病院研修医
平成 1 7 年	5 月	慶應義塾大学医学部助手（専修医）（泌尿器科学）
平成 1 8 年	4 月	川崎市立川崎病院 泌尿器科医員
平成 1 9 年	4 月	神奈川県警友会 けいゆう病院 泌尿器科医員
平成 2 0 年	4 月	慶應義塾大学助教（医学部泌尿器科学）
平成 2 4 年	4 月	東京都済生会中央病院泌尿器科 医員
平成 2 7 年	8 月	ハーバード大学 Dana-Farber 癌研究所 研究員
平成 2 9 年	9 月	川崎市立川崎病院 泌尿器科医長
令和 3 年	4 月	東京都済生会中央病院泌尿器科 医員
令和 4 年	2 月	医療法人財団佐花会大井中央病院 理事長

資格

医学博士
日本泌尿器科学会専門医
日本がん治療認定医機構がん治療認定医
日本臨床泌尿器科医会 幹事

賞罰

2009 年 10 月	第 74 回日本泌尿器科学会東部総会優秀演題ポスター賞
2009 年 10 月	第 47 回日本癌治療学会学術集会 婦人科／泌尿器領域 優秀演題賞
2012 年 6 月	第 31 回日本アンドロロジー学会 学会賞
2012 年 9 月	第 23 回日本性機能学会 学会賞
2019 年 4 月	日本泌尿器科学会 坂口賞
2019 年 6 月	第 38 回日本アンドロロジー学会学術奨励賞

業績 競争の研究費

2010 年科研費若手研究 (B) マウス閉塞性水腎症に対する新規 AP-1 阻害剤による腎線維化の制御

2013 年科研費若手研究 (B) 5α 還元酵素阻害剤のステロイドホルモンとメンズヘルスに与える影響

業績論文

筆頭著者

1.

Change of the 5 α /5 β ratio of urinary steroid metabolites in benign prostatic hyperplasia patients treated with dutasteride.

Maeda T, Kikuchi E, Hasegawa M, Homma K, Yasumizu Y, Hattori S, Kosaka T, Shinoda K, Miyajima A, Oya M.

Clin Biochem. 2018 May;55:36-41. doi: 10.1016/j.clinbiochem.2018.03.021. Epub 2018 Mar 31.

2.

Influence of dutasteride treatment on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement.

Maeda T, Kikuchi E, Hasegawa M, Homma K, Ando T, Suzuki K, Kaneko G, Mizuno R, Miyajima A, Oya M.

Int J Urol. 2018 Jan;25(1):70-74. doi: 10.1111/iju.13470. Epub 2017 Oct 3.

3.

MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.

Maeda T, Hiraki M, Jin C, Rajabi H, Tagde A, Alam M, Bouillez A, Hu X, Suzuki Y, Miyo M, Hata T, Hinohara K, Kufe D.

Cancer Res. 2018 Jan 1;78(1):205-215. doi: 10.1158/0008-5472.CAN-17-1636. Epub 2017 Dec 20.

4.

Female Functional Constipation Is Associated with Overactive Bladder Symptoms and Urinary Incontinence.

Maeda T, Tomita M, Nakazawa A, Sakai G, Funakoshi S, Komatsuda A, Ito Y, Nagata H, Tsukada N, Nakamura S.

Biomed Res Int. 2017;2017:2138073. doi: 10.1155/2017/2138073. Epub 2017 Feb 28.

5.

Obstructive sleep apnea syndrome should be considered as a cause of nocturia in younger patients without other voiding symptoms.

Maeda T, Fukunaga K, Nagata H, Haraguchi M, Kikuchi E, Miyajima A, Yamasawa W, Shirahama R, Narita M, Betsuyaku T, Asano K, Oya M.

Can Urol Assoc J. 2016 Jul-Aug;10(7-8):E241-E245. doi: 10.5489/cuaj.3508. Epub 2016

Jul 12.

6.

A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride.

Maeda T, Kikuchi E, Hasegawa M, Ando T, Matsushima M, Yuge K, Ito Y, Miyajima A, Oya M.

Aging Male. 2016 Jun;19(2):111-6. doi: 10.3109/13685538.2016.1156082. Epub 2016 Mar 10.

7.

Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia.

Maeda T, Kikuchi E, Hasegawa M, Ishioka K, Hagiwara M, Miyazaki Y, Shinojima T, Miyajima A, Oya M.

Urology. 2015 May;85(5):1151-1155. doi: 10.1016/j.urology.2015.01.028. Epub 2015 Mar 12.

8.

Evaluation of histopathological findings at the injection site following degarelix administration.

Maeda T, Kosaka T, Honda A, Okata U, Hayakawa N, Ito Y, Nagata H, Chen KR, Nakamura S, Oya M.

Support Care Cancer. 2015 May;23(5):1377-81. doi: 10.1007/s00520-014-2483-x. Epub 2014 Oct 31.

9.

Editorial comment to Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.

Maeda T.

Int J Urol. 2014 Aug;21(8):819-20. doi: 10.1111/iju.12521. Epub 2014 Jun 17.

10.

Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.

Maeda T, Kikuchi E, Matsumoto K, Miyajima A, Oya M.

J Urol. 2011 Mar;185(3):802-6. doi: 10.1016/j.juro.2010.10.081. Epub 2011 Jan 15.

11.

Renal cell carcinoma accompanied by left-sided IVC.

Maeda T, Miyajima A, Kikuchi E, Oya M.

Intern Med. 2011;50(10):1127. doi: 10.2169/internalmedicine.50.5235. Epub 2011 May

12.

Gemcitabine and cisplatin chemotherapy induced reversible posterior leukoencephalopathy syndrome in a bladder cancer patient.

Maeda T, Kikuchi E, Matsumoto K, Yazawa S, Hagiuda J, Miyajima A, Nakagawa K, Fujiwara H, Hoshino H, Oya M.

Int J Clin Oncol. 2010 Oct;15(5):508-11. doi: 10.1007/s10147-010-0068-3. Epub 2010 Mar 30.

13

Thrombosis in inferior vena cava due to enlarged renal cysts in autosomal dominant polycystic kidney disease.

Maeda T, Uchida Y, Oyamada K, Nakajima F.

Intern Med. 2010;49(17):1891-4. doi: 10.2169/internalmedicine.49.3748. Epub 2010 Sep 1.

14

Vesical endometriosis following the menopause.

Maeda T, Uchida Y, Nakajima F.

Int Urogynecol J Pelvic Floor Dysfunct. 2009 Dec;20(12):1515-7. doi: 10.1007/s00192-009-0925-7. Epub 2009 Jun 17.

15.

Pheochromocytoma with chronic renal failure: a case report.

Maeda T, Kozakai N, Nishiyama T, Sugiura H, Nakamura K.

Hinyokika Kiyo. 2009 Jul;55(7):409-12.

16.

Gastric metastasis from renal cell carcinoma 20 months after radical nephrectomy: a case report.

Maeda T, Kozakai N, Nishiyama T, Ishii T, Sugiura H, Nakamura K.
Hinyokika Kiyo. 2009 Mar;55(3):137-40.

17.

Metastatic malignant melanoma of the urinary bladder presenting with hematuria: a case report.

Maeda T, Uchida Y, Kouda T, Matsui H, Kawahara Y, Sato T, Nakajima F.
Hinyokika Kiyo. 2008 Dec;54(12):787-90.

共同著者

1.

Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma

Tetsushi Murakami, Eiji Kikuchi, Hiroki Ide, Yuta Umezawa, Takayuki Takahashi, Mizuki Izawa, Kyohei Hakozaki, Keisuke Shigeta, Koichiro Ogihara, Hiroaki Kobayashi, Kunimitsu Kanai, **Takahiro Maeda**, Shunsuke Yoshimine, Ryuichi Mizuno, Koshiro Nishimoto, Mototsugu Oya

BJUI Compass 2021 Mar 9;2(5):322-330. doi: 10.1002/bco2.81. eCollection 2021 Sep.

2.

Significance of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer

Kyohei Hakozaki, Eiji Kikuchi, Koichiro Ogihara, Keisuke Shigeta, Takayuki Abe, Yasumasa Miyazaki, Gou Kaneko, **Takahiro Maeda**, Shunsuke Yoshimine, Kunimitsu Kanai, Hiroki Ide, Suguru Shirotake, Masafumi Oyama, Ryuichi Mizuno, Mototsugu Oya
Jpn J Clin Oncol 2021 Feb 8;51(2):287-295. doi: 10.1093/jjco/hyaa168.

3.

Hand-assisted laparoscopic ileal ureter substitution for ureteral obstruction after right ureteral rupture: A case report

Masahiro Katsui, Kota Umeda, Seiya Hattori, Toshiyuki Ando, **Maeda Takahiro**, Satoshi Hara

Urol Case Rep 2020 Jun 24;33:101326. doi: 10.1016/j.eucr.2020.101326.

4.

MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.

Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, **Maeda T**, Kosaka T, Wong KK, Oya M, Kufe D.

Nat Commun. 2020 Jan 17;11(1):338. doi: 10.1038/s41467-019-14219-6.

5.

MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.

Yamamoto M, Jin C, Hata T, Yasumizu Y, Zhang Y, Hong D, **Maeda T**, Miyo M, Hiraki M, Suzuki Y, Hinohara K, Rajabi H, Kufe D.

Cancer Res. 2019 Apr 15;79(8):2031-2041. doi: 10.1158/0008-5472.CAN-18-3259. Epub 2019 Mar 1.

6.

Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer.

Hata T, Rajabi H, Yamamoto M, Jin C, Ahmad R, Zhang Y, Kui L, Li W, Yasumizu Y, Hong D, Miyo M, Hiraki M, **Maeda T**, Suzuki Y, Takahashi H, Samur M, Kufe D.

Mol Cancer Ther. 2019 Oct;18(10):1744-1754. doi: 10.1158/1535-7163.MCT-19-0156. Epub 2019 Jul 15.

7.

MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.

Hata T, Rajabi H, Takahashi H, Yasumizu Y, Li W, Jin C, Long MD, Hu Q, Liu S, Fushimi A, Yamashita N, Kui L, Hong D, Yamamoto M, Miyo M, Hiraki M, **Maeda T**, Suzuki Y, Samur MK, Kufe D.

Cancer Res. 2019 Nov 15;79(22):5711-5722. doi: 10.1158/0008-5472.CAN-19-1034. Epub 2019 Sep 13.

8.

History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.

Kayama E, Kikuchi E, Fukumoto K, Shirotake S, Miyazaki Y, Hakozaki K, Kaneko G, Yoshimine S, Tanaka N, **Takahiro M**, Kanai K, Oyama M, Nakajima Y, Hara S, Monma

T, Oya M.

Clin Genitourin Cancer. 2018 Oct;16(5):e969-e976. doi: 10.1016/j.clgc.2018.04.004. Epub 2018 Apr 28.

9.

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer.

Hiraki M, Maeda T, Mehrotra N, Jin C, Alam M, Bouillez A, Hata T, Tagde A, Keating A, Kharbanda S, Singh H, Kufe D.

Signal Transduct Target Ther. 2018 May 12;3:13. doi: 10.1038/s41392-018-0013-x. eCollection 2018.

10.

Significance of a frozen section analysis of the ureteral margin in bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapy.

Hakozaki K, Kikuchi E, Fukumoto K, Shirotake S, Miyazaki Y, **Maeda T**, Kaneko G, Yoshimine S, Tanaka N, Kanai K, Oyama M, Nakajima Y, Momma T, Oya M.

Med Oncol. 2017 Oct 23;34(12):187. doi: 10.1007/s12032-017-1048-5.

11.

MUC1-C activates BMI1 in human cancer cells.

Hiraki M, **Maeda T**, Bouillez A, Alam M, Tagde A, Hinohara K, Suzuki Y, Markert T, Miyo M, Komura K, Ahmad R, Rajabi H, Kufe D.

Oncogene. 2017 May 18;36(20):2791-2801. doi: 10.1038/onc.2016.439. Epub 2016 Nov 28.

12.

MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.

Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, Alam M, Hiraki M, **Maeda T**, Hu X, Adeegbe D, Kharbanda S, Wong KK, Kufe D.

Oncogene. 2017 Jul 13;36(28):4037-4046. doi: 10.1038/onc.2017.47. Epub 2017 Mar 13.

13.

Characterizing intermediate-risk non-muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy.

Matsumoto K, Kikuchi E, Yanai Y, Hayakawa N, Ito Y, **Maeda T**, Nagata H, Miyajima A, Oya M.

Urol Oncol. 2017 May;35(5):208-214. doi: 10.1016/j.urolonc.2016.11.014. Epub 2017 Jan 3.

14.

Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.

Hasegawa M, Takahashi H, Rajabi H, Alam M, Suzuki Y, Yin L, Tagde A, **Maeda T**, Hiraki M, Sukhatme VP, Kufe D.

Oncotarget. 2016 Mar 15;7(11):11756-69. doi: 10.18632/oncotarget.7598.

15.

MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway.

Alam M, Bouillez A, Tagde A, Ahmad R, Rajabi H, **Maeda T**, Hiraki M, Suzuki Y, Kufe D.

Mol Cancer Res. 2016 Dec;14(12):1266-1276. doi: 10.1158/1541-7786.MCR-16-0233. Epub 2016 Sep 22.

16.

Clinical Background of Patients with Sperm in Their Urinary Sediment.

Tomita M, Kikuchi E, **Maeda T**, Kabeya Y, Katsuki T, Oikawa Y, Kato K, Ohashi M, Nakamura S, Oya M, Shimada A.

PLoS One. 2015 Sep 11;10(9):e0136844. doi: 10.1371/journal.pone.0136844. eCollection 2015.

17.

Comparison of outcomes between ultrasonography and cystoscopy in the surveillance of patients with initially diagnosed TaG1-2 bladder cancers: A matched-pair analysis.

Niwa N, Matsumoto K, Hayakawa N, Ito Y, **Maeda T**, Akatsuka S, Masuda T, Nakamura S, Tanaka N.

Urol Oncol. 2015 Sep;33(9):386.e15-21. doi: 10.1016/j.urolonc.2015.04.018. Epub 2015 May 28.

18.

The role of single instillation chemotherapy in patients who receive subsequent bacillus Calmette-Guérin: A retrospective single centre study, and systematic review of the literature.

Matsumoto K, Gondo T, Hayakawa N, **Maeda T**, Ninomiya A, Nakamura S.
Can Urol Assoc J. 2015 Jul-Aug;9(7-8):E411-6. doi: 10.5489/cuaj.2818.

19.

Preoperative parameters to predict incidental (T1a and T1b) prostate cancer.

Sakamoto H, Matsumoto K, Hayakawa N, **Maeda T**, Sato A, Ninomiya A, Mukai K, Nakamura S.
Can Urol Assoc J. 2014 Nov;8(11-12):E815-20. doi: 10.5489/cuaj.1890.

20.

Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy.

Hayakawa N, Matsumoto K, Sato A, Sakamoto H, Ezaki T, **Maeda T**, Ninomiya A, Nakamura S.
Int Urol Nephrol. 2014 Jun;46(6):1123-9. doi: 10.1007/s11255-013-0634-5. Epub 2013 Dec 20.

21.

Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression.

Kobayashi H, Kikuchi E, Mikami S, **Maeda T**, Tanaka N, Miyajima A, Nakagawa K, Oya M.
BMC Urol. 2014 Jan 8;14:5. doi: 10.1186/1471-2490-14-5.

22.

Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: report of 52 cases and literature review.

Matsumoto K, Hagiwara M, Hayakawa N, Tanaka N, Ito Y, **Maeda T**, Ninomiya A, Nagata H, Nakamura S.
Asian Pac J Cancer Prev. 2014;15(8):3645-9. doi: 10.7314/apjcp.2014.15.8.3645.

23.

Visceral fat is correlated with prolonged operative time in laparoendoscopic single-site adrenalectomy and laparoscopic adrenalectomy.

Hasegawa M, Miyajima A, Jinzaki M, **Maeda T**, Takeda T, Kikuchi E, Shibata H, Oya M.

Urology. 2013 Dec;82(6):1312-8. doi: 10.1016/j.urology.2013.05.063. Epub 2013 Oct 16.

24.

Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature.

Matsumoto K, Tanaka N, Hayakawa N, Ezaki T, Suzuki K, **Maeda T**, Ninomiya A, Nakamura S.

Med Oncol. 2013 Dec;30(4):717. doi: 10.1007/s12032-013-0717-2. Epub 2013 Sep 5.

25.

Three cases of IgG4-related disease associated with urinary tract obstruction.

Yazawa S, Ohara R, **Maeda T**, Kanao K, Hattori S, Nakajima Y, Oya M.

Nihon Hinyokika Gakkai Zasshi. 2013 Jul;104(4):620-5. doi: 10.5980/jpnjurol.104.620.

26.

How can lymphocele development be prevented after laparoscopic radical prostatectomy?

Yasumizu Y, Miyajima A, **Maeda T**, Takeda T, Hasegawa M, Kosaka T, Kikuchi E, Oya M.

J Endourol. 2013 Apr;27(4):447-51. doi: 10.1089/end.2012.0356. Epub 2012 Dec 5.

27.

A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy.

Matsushima M, Kikuchi E, **Maeda T**, Nakashima J, Sugawara A, Ando T, Mizuno R, Nagata H, Miyajima A, Shigematsu N, Oya M.

J Urol. 2013 Mar;189(3):1014-8. doi: 10.1016/j.juro.2012.09.086. Epub 2012 Sep 24.

28.

Does laparoendoscopic single-site adrenalectomy increase surgical risk in patients with pheochromocytoma?

Hattori S, Miyajima A, **Maeda T**, Hasegawa M, Takeda T, Kosaka T, Kikuchi E,

Nakagawa K, Oya M.

Surg Endosc. 2013 Feb;27(2):593-8. doi: 10.1007/s00464-012-2495-x. Epub 2012 Oct 6.

29.

The type of patients who would benefit from anti-androgen withdrawal therapy: could it be performed safely for aggressive prostate cancer?

Matsumoto K, Tanaka N, Hayakawa N, Ezaki T, Suzuki K, **Maeda T**, Ninomiya A, Nakamura S.

Med Oncol. 2013;30(3):647. doi: 10.1007/s12032-013-0647-z. Epub 2013 Jun 25.

30.

Human castration resistant prostate cancer rather prefer to decreased 5 α -reductase activity.

Kosaka T, Miyajima A, Nagata H, **Maeda T**, Kikuchi E, Oya M.

Sci Rep. 2013;3:1268. doi: 10.1038/srep01268.

31.

Risk factors for perioperative complications of laparoscopic adrenalectomy including single-site surgery.

Hattori S, Miyajima A, **Maeda T**, Hasegawa M, Takeda T, Kosaka T, Kikuchi E, Nakagawa K, Shibata H, Oya M.

J Endourol. 2012 Nov;26(11):1463-7. doi: 10.1089/end.2012.0274. Epub 2012 Sep 10.

32.

Metastatic urothelial carcinoma to pericardia manifested by dyspnea from cardiac tamponade during systemic chemotherapy: Case report and literature review.

Hattori S, Miyajima A, **Maeda T**, Takeda T, Morita S, Kosaka T, Kikuchi E, Oya M.

Can Urol Assoc J. 2012 Oct;6(5):E184-8. doi: 10.5489/cuaj.11130.

33.

Does pelvic lymph node dissection improve the biochemical relapse-free survival in low-risk prostate cancer patients treated by laparoscopic radical prostatectomy?

Daimon T, Miyajima A, **Maeda T**, Hattori S, Yasumizu Y, Hasegawa M, Kosaka T, Kikuchi E, Nakagawa K, Oya M.

J Endourol. 2012 Sep;26(9):1199-202. doi: 10.1089/end.2011.0589. Epub 2012 Jun 25.

34.

Renal cell carcinoma arising from a horseshoe kidney in a chronic hemodialysis patient.
Miyazaki Y, Miyajima A, **Maeda T**, Ito Y, Tanaka N, Kosaka T, Masuda A, Mizuno R,
Kikuchi E, Nakagawa K, Oya M.

Clin Exp Nephrol. 2012 Aug;16(4):647-51. doi: 10.1007/s10157-012-0661-z. Epub 2012
Jun 28.

35.

The prognostic significance of vasohibin-1 expression in patients with upper urinary tract
urothelial carcinoma.

Miyazaki Y, Kosaka T, Mikami S, Kikuchi E, Tanaka N, **Maeda T**, Ishida M, Miyajima
A, Nakagawa K, Okada Y, Sato Y, Oya M.

Clin Cancer Res. 2012 Aug 1;18(15):4145-53. doi: 10.1158/1078-0432.CCR-12-0073.
Epub 2012 Jun 6.

36.

Transumbilical approach for laparo-endoscopic single-site adrenalectomy: initial
experience and short-term outcome.

Miyajima A, Hattori S, **Maeda T**, Hasegawa M, Takeda T, Kikuchi E, Asanuma H,
Nakagawa K, Oya M.

Int J Urol. 2012 Apr;19(4):331-5. doi: 10.1111/j.1442-2042.2011.02932.x. Epub 2011
Dec 14.

37.

Extrapancreatic solid pseudopapillary tumor: case report and review of the literature.

Miyazaki Y, Miyajima A, **Maeda T**, Yuge K, Hasegawa M, Kosaka T, Kikuchi E,
Kameyama K, Jinzaki M, Nakagawa K, Oya M.

Int J Clin Oncol. 2012 Apr;17(2):165-8. doi: 10.1007/s10147-011-0261-z. Epub 2011 Jun
9.

38.

Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human
castration resistant prostate cancer.

Hasegawa M, Miyajima A, Kosaka T, Yasumizu Y, Tanaka N, **Maeda T**, Shirotake S, Ide
H, Kikuchi E, Oya M.

Int J Cancer. 2012 Jan 15;130(2):431-42. doi: 10.1002/ijc.26012. Epub 2011 Apr 25.

40.

Transumbilical laparo-endoscopic single site surgery for adrenal cortical adenoma inducing primary aldosteronism: initial experience.

Miyajima A, **Maeda T**, Hasegawa M, Takeda T, Ishida M, Kosaka T, Kikuchi E, Nakagawa K, Oya M.

BMC Res Notes. 2011 Sep 24;4:364. doi: 10.1186/1756-0500-4-364.

41.

Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer.

Shirotake S, Miyajima A, Kosaka T, Tanaka N, **Maeda T**, Kikuchi E, Oya M.

Urology. 2011 Apr;77(4):1009.e19-25. doi: 10.1016/j.urology.2010.11.002. Epub 2011 Feb 5.

42.

Initial experience of transumbilical laparoendoscopic single-site surgery of partial adrenalectomy in patient with aldosterone-producing adenoma.

Yuge K, Miyajima A, Hasegawa M, Miyazaki Y, **Maeda T**, Takeda T, Takeda A, Miyashita K, Kurihara I, Shibata H, Kikuchi E, Oya M.

BMC Urol. 2010 Nov 23;10:19. doi: 10.1186/1471-2490-10-19.

43.

Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.

Shinoda K, Nakagawa K, Kosaka T, Tanaka N, **Maeda T**, Kono H, Mizuno R, Kikuchi E, Miyajima A, Umezawa K, Oya M.

Hum Immunol. 2010 Aug;71(8):763-70. doi: 10.1016/j.humimm.2010.05.009. Epub 2010 May 24.